The Systolic Hypertension in Europe (Syst-Eur) study investigated whether antihypertensive
treatment could decrease the risk of cardiovascular complications in elderly patients with …

The Syst-Eur study investigated whether active antihypertensive treatment could reduce
cardiovascular complications in elderly patients with isolated systolic hypertension …

Abstract The Syst-Eur trial investigated whether active treatment starting with the
dihydropyridine calcium channel blocker (CCB) nitrendipine, could reduce the …

Background In 1989, the European Working Party on High Blood Pressure in the Elderly
started the double-blind, placebo-controlled, Systolic Hypertension in Europe Trial to test the …

Aims: Isolated systolic hypertension affects over 8 to 15% of all subjects older than 60 years.
In the elderly, systolic hypertension is the major modifiable cardiovascular risk factor. Three …

Isolated systolic hypertension (ISH) has proved to be a powerful predisposing factor for
cardiovascular diseases in the elderly. Recent placebo-controlled interventional trials such …

Hypertension is one of the main risk factors for cerebrovascular disease (stroke), coronary
artery disease (acute myocardial infarction), congestive heart failure (both systolic and …

Background Previous meta-analysis of outcome trials in hypertension have not specifically
focused on isolated systolic hypertension or they have explained treatment benefit mainly in …

The pharmacological treatment, mainly based on diuretics, of isolated systolic hypertension
(ISH) has recently been shown to reduce the risk of stroke and coronary heart disease in the …

Isolated systolic hypertension affects over 15% of all people older than 60 years of age. In
the elderly, systolic hypertension is a major modifiable cardiovascular risk factor. Systolic …